Report LibraryAll Reports
Datamonitor Healthcare Oncology: Small Cell Lung Cancer (SCLC) Market Spotlight
Retail Price: $2,995.00*BioMedTracker Subscriber Price: $2,095.00 - click here to log in
August 07, 2018SCLC is a fast-growing cancer of neuroendocrine origin that develops in the lungs and has a tendency to metastasize extensively and early in the course of the disease. It accounts for about 15% of all cases of lung cancer. Of these 15% of patients, approximately 30% are diagnosed with limited-stage disease, confined to one hemithorax. At the time of diagnosis, the majority of patients have extensive-stage disease, in which the tumor spreads beyond one hemithorax. SCLC’s standard staging procedures include computed tomography (CT) scans of the abdomen, chest, and bone, and magnetic resonance imaging (MRI) or CT scans of the brain.
This Datamonitor Healthcare report contains a Market Spotlight module.
|Disease Group Covered:||Oncology|